Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922440 · ClinicalTrials.gov registry record
A Registry for Participants With Chronic Hypoparathyroidism
A clinical trial of Hypoparathyroidism, sponsored by Takeda.
- Active
- Registry status
- 1,339
- Enrollment target
- 20
- Study locations
NCT01922440: Active study of Hypoparathyroidism, sponsored by Takeda.
NCT01922440 is a study of Hypoparathyroidism that is active but no longer recruiting, run by Takeda. The registered enrollment target is 1,339 participants, above the 66-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (1929% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01922440, a study of Hypoparathyroidism, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- 1,339 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.
Primary Outcome
Change from baseline in 24-hour urine calcium will be evaluated.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (20)
Illinois
- Suburban Endocrinology & Diabetes - Arlington Heights
- University of Chicago Medical Center - Chicago
- Northshore University Health System - Evanston
- Loyola University Medical Center - Maywood
California
- Children's Hospital Los Angeles - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Dr. Joselito Cabaccan - San Jose
Florida
- Hanson Clinical Research Center - Port Charlotte
- Thyroid & Endocrine Center of Florida - Sarasota
Maryland
- Model Clinical Research - Baltimore
- Medstar Union Memorial Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- University of Arizona Medical Center - Tucson
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,339 participants |
| Start Date | 2013-07-30 |
| Est. Completion | 2034-11-30 |
What the registry record for NCT01922440 still lists
NCT01922440 is an observational study that tracks outcomes without assigning an intervention. Its 1,339 participants enrollment target places it among the larger protocols in the corpus, above the 66-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (1929% higher).
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT01922440 names 20 study sites across 12 states, led by Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01922440 about?
NCT01922440 is a clinical study titled "A Registry for Participants With Chronic Hypoparathyroidism". The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to...
What is the current status of trial NCT01922440?
This trial is currently active not recruiting. The enrollment target is 1,339 participants. The study started on 2013-07-30. Estimated completion is 2034-11-30.
What conditions does trial NCT01922440 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
What interventions are being tested in trial NCT01922440?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT01922440?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01922440 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01922440's enrollment target sits among peer trials
1,339 1st of 10 higher than 10 of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06972056 · 1,335 participants · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI